Vnitr Lek 2000, 46(3):157-160
[Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
- Za skupinu spolupracujících center Klinického sledování úcinnosti lipanoru III. interní klinika 1, Praha.
Klíčová slova: Clofibric Acid, analogs & derivatives, ; Female; Fibric Acids; Humans; Hyperlipoproteinemias, drug therapy, ; Hypolipidemic Agents, therapeutic use, ; Male; Middle Aged
A total of 633 patients with combined hyperlipoproteinaemia from 23 centres in the Czech Republic met the criteria for assessment of the effectiveness of 3-month administration of 100 mg ciprofibrate (Lipanor) per day. The cholesterol concentration declined from the original values of 6.94 mmol/l by 13%. The drop of triglycerides was even more significant from 3.03 mmol/l by more than 41%. The relatively low HDL cholesterol at the beginning, 1.14 mmol/l, increased by 15%, while LDL-cholesterol dropped significantly by almost 12%. The classical atherogenic index expressed by the ratio of total/HDL cholesterol declined by 25%. Treatment was very well tolerated by the patients and was associated with a minimum of undesirable side-effects. Treatment with ciprofibrate is effective and safe treatment in patients with combined hyperlipoproteinaemia.
Keywords: Clofibric Acid /analogs & derivatives/; Female; Fibric Acids; Humans; Hyperlipoproteinemias /drug therapy/; Hypolipidemic Agents /therapeutic use/; Male; Middle Aged
Zveřejněno: 1. březen 2000 Zobrazit citaci
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |